Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31572376 | 0.78 | VEGFA (0.50) | GPR119SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL31271638 | 0.78 | CHRM2 (0.44) | GPR119CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9933243 | 0.77 | CHRM2 (0.46) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL17271685 | 0.75 | FAAH (0.53) | GPR119USP2SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL207984 | 0.74 | CHRM2 (0.44) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL465696 | 0.74 | TBK1 (0.51) | GPR119CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL20503491 | 0.74 | GPR119 (0.47) | GPR119 | |
| SCHEMBL21614471 | 0.73 | USP30 (0.51) | GPR119USP2SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL16892052 | 0.73 | VEGFA (0.50) | GPR119CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL18191713 | 0.73 | PIK3CA (0.46) | GPR119CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864328-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447092-B2 | Pharmaceutically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266868-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | FLT3, AURKC, AURKA | GPR119 1554/4885USP2 4480/4885SMN1; SMN2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.